

October 27, 2021

To whom it may concern:

Company Name TOHO HOLDINGS CO., LTD.
 Corporate Representative Atsushi Udoh, President and Representative Director
 (First Section of Tokyo Stock Exchange Securities Code:8129)
 Contact: Makoto Kawamura, Director and General Manager, Corporate Management Division and Corporate Planning and Investor Relations Department
 (TEL: 81-3-6838-2803)

Notice Regarding Approval of Partial Amendments to Indications, Dosage and Administration of Imatinib Tablets 100mg “KMP” for KYOSOMIRAI PHARMA

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Nobuaki Hosaka), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, received an approval of partial amendments to indications, dosage and administration of Imatinib Tablets 100mg “KMP” on October 27, 2021 as below.

Outline of Imatinib Tablets 100mg “KMP”

Classes	Product Name	Original Brand Name
Antineoplastic agent (Tyrosine kinase inhibitor)	Imatinib Tablets 100mg “KMP”	Glivec®Tablets 100mg

Outline of Amendments to Indications, Dosage and Administration of Imatinib Tablets 100mg “KMP”

Indications and Usage	<ul style="list-style-type: none"> ○Chronic myelogenous leukemia ○<u>KIT (CD117) positive gastrointestinal stromal tumor</u> ○Philadelphia chromosome-positive acute lymphocytic leukemia
Dosage and Administration	<ul style="list-style-type: none"> ○Chronic myelogenous leukemia Chronic phase: the usual dosage for adult patients is 400 mg as imatinib orally taken once daily after a meal. The dose should be adjusted according to the patient’s hematological finding, age and symptoms. The dosage may be increased up to 600 mg once daily. Transition or acute phase: the usual dosage for adult patients is 600 mg as imatinib orally taken once daily after a meal. The dose should be adjusted according to the patient’s hematological finding, age and symptoms. The dosage may be increased up to 800 mg daily (400 mg twice a day). ○<u>KIT (CD117) positive gastrointestinal stromal tumor</u> <u>The usual dosage for adult patients is 400 mg as imatinib orally taken once daily after a meal. The dose should be reduced depending on the patient’s age and symptoms.</u> ○Philadelphia chromosome-positive acute lymphocytic leukemia The usual dosage for adult patients is 600 mg as imatinib orally taken once daily after a meal. The dose should be reduced according to the patient’s hematological finding, age and symptoms.

(Underlined parts are revised parts.)